---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001869"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T19:56:20.367022+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aptose reports Q4 net loss $10.0M; cash runway into Q1 2024; tuspetinib expansion trial underway

## Summary
- Q4 net loss $10.0M ($0.11/sh) vs $24.3M loss year ago; FY2022 net loss $41.8M ($0.45/sh) vs $65.4M.
- Cash and investments $47.0M at Dec 31, 2022; expects funding into Q1 2024.
- APTIVATE Phase 1/2 expansion trial for tuspetinib initiated; monotherapy and TUS/VEN combination arm enrolling.
- Tuspetinib monotherapy showed 29% CR/CRh in RAS-mutated AML patients during dose escalation.
- Luxeptinib G3 formulation shows improved bioavailability; continuous dosing ongoing.

## SEC filing metadata
- accession: 0001171843-23-001869
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184323001869/0001171843-23-001869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184323001869/f8k_032323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001869
- JSON: https://secwatch.observer/filing/0001171843-23-001869.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001869.txt

## Key facts
- Earnings Releases
  Aptose Biosciences Inc. reported the quarter ended December 31, 2022 results: net income $10.0 million, EPS ($0.11 per share).
  - Period: the quarter ended December 31, 2022
  - Net income: $10.0 million
  - EPS: ($0.11 per share)
  - Result: reported results
  source text: The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared with $24.3 million ($0.27 per share) for the quarter ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184323001869/0001171843-23-001869-index.htm
- Earnings Releases
  Aptose Biosciences Inc. reported the year ended December 31, 2022 results: net income $41.8 million, EPS ($0.45 per share).
  - Period: the year ended December 31, 2022
  - Net income: $41.8 million
  - EPS: ($0.45 per share)
  - Result: reported results
  source text: The net loss for the year ended December 31, 2022, was $41.8 million ($0.45 per share) compared with $65.4 million ($0.73 per share) for the year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184323001869/0001171843-23-001869-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.